IL-6 signalling in patients with acute ST-elevation myocardial infarction

Results in Immunology

Volumn 4, Issue 1, 2014, Pages 8-13

  Ritschel, Vibeke N ^a,b,c   Seljeflot, Ingebjørg ^a,b,c   Arnesen, Harald ^a,b,c   Halvorsen, Sigrun ^a,b   Weiss, Thomas ^d   Eritsland, Jan ^a,b   Andersen, Geir Ø ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d WILHELMINEN HOSPITAL   (Austria)

Author keywords

IL 6; Myocardial necrosis; Sgp130; SIL 6R; ST elevation myocardial infarction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; GLYCOPROTEIN GP 130; HEMOGLOBIN A1C; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TROPONIN T;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DYSGLYCEMIA; FEMALE; GLUCOSE METABOLISM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE NECROSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; CORRELATION ANALYSIS; HEART INFARCTION SIZE; MIDDLE AGED; RISK FACTOR;

EID: 84897447531     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2013.11.002     Document Type: Article

References (28)

1. Libby P Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Libby P, Ridker PM, Maseri A Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
3. Frangogiannis NG, Smith CW, Entman ML The inflammatory response in myocardial infarction. Cardiovascular Research 2002, 53:31-47.
4. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK Chemokines in cardiovascular risk prediction. Thrombosis and Haemostasis 2007, 97:748-754.
5. Young JL, Libby P, Schonbeck U Cytokines in the pathogenesis of atherosclerosis. Thrombosis and Haemostasis 2002, 88:554-567.
6. Karpinski L, Plaksej R, Kosmala W, Witkowska M Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiologia polska 2008, 66:1279-1285.
7. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta 2011, 1813:878-888.
8. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thrombosis and Haemostasis 2009, 102:215-222.
9. Szabo-Fresnais N, Lefebvre F, Germain A, Fischmeister R Pomerance M. A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. Cell Signal 2010, 22:1143-1152.
10. Rose-John S, Scheller J, Elson G, Jones SA Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. Journal of Leukocyte Biology 2006, 80:227-236.
11. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. European Journal of Biochemistry 2001, 268:160-167.
12. Diabetes American Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(Suppl. 1):S64-S71.
13. Rose-John S Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochimica Polonica 2003, 50:603-611.
14. Orn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. European Heart Journal 2009, 30:1180-1186.
15. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlof B, et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circulation: Arrhythmia and Electrophysiology Archives 2013, 6:243-251.
16. Bossowska A, Kiersnowska-Rogowska B, Bossowski A, Galar B, Sowinski P Cytokines in patients with ischaemic heart disease or myocardial infarction. Kardiologia Polska 2003, 59:105-114.
17. Kaminski KA, Kozuch M, Bonda T, Wojtkowska I, Kozieradzka A, Dobrzycki S, et al. Coronary sinus concentrations of interleukin 6 and its soluble receptors are affected by reperfusion and may portend complications in patients with myocardial infarction. Atherosclerosis 2009, 206:581-587.
18. Ichiki T, Jougasaki M, Setoguchi M, Shimokawahara H, Nakashima H, Matsuoka T, et al. Plasma levels of soluble glycoprotein 130 in acute myocardial infarction. Journal of Cardiology 2007, 50:101-119.
19. van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, et al. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Journal of Thrombosis and Thrombolysis 2012, 34:106-113.
20. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology 1999, 83:376-382.
21. Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Circulation: Heart Failure 2013, 6:91-98.
22. Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 2004, 19:237-241.
23. Zuliani G, Galvani M, Maggio M, Volpato S, Bandinelli S, Corsi AM, et al. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis 2010, 213:319-324.
24. Weiss TW, Arnesen H, Seljeflot I Components of the Interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism 2013, 62:1008-1013.
25. Bonda T, Kaminski KA, Kozuch M, Kozieradzka A, Wojtkowska I, Dobrzycki S, et al. Circadian variations of interleukin 6 in coronary circulations of patients with myocardial infarction. Cytokine 2010, 50:204-209.
26. Hartford M, Wiklund O, Mattsson Hulten L, Perers E, Person A, Herlitz J, et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. International Journal of Cardiology 2006, 108:55-62.
27. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. European Heart Journal 2005, 26:1964-1970.
28. Solheim S, Grogaard HK, Hoffmann P, Arnesen H, Seljeflot I Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. Scandinavian Journal of Clinical and Laboratory Investigation 2008, 68:555-562.